SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RUM Group, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

RUM is drawing attention after reporting record Q3 revenue above guidance and its first profitable quarter on an adjusted EBITDA basis, with Quake AI driving much of the growth. Bullish traders point to AI demand and heavy short interest as potential squeeze fuel, while skeptics focus on softer Q4 guidance, possible data-center delays and the financing required for expansion.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors Q3 call reaffirmed confidence in deramiocel and said its application is in final FDA review ahead of the Nov. 22 decision for Duchenne muscular dystrophy. Traders are largely optimistic and reading managements comments as signs approval may be near, but others stress the outcome remains binary, with rejection risk and uncertainty around the drugs label.

Zcash (ZEC) is a cryptocurrency . Users are able to generate ZEC through the process of mining. Zcash has a current supply of 16,959,453.18587388 with 16,959,453.64420722 in circulation. The last known price of Zcash is 1,033.61575403 USD and is down -11.66 over the last 24 hours. It is currently trading on 670 active market(s) with $1,322,935,861.71 traded over the last 24 hours. More information can be found at https://z.cash/.

Zcash

Zcash is drawing attention for a sharp, volatile pullback after a major run, with traders debating whether it is a routine consolidation or a deeper breakdown amid weakness and liquidations across crypto. Bulls are buying the dip and pointing to Zcashs privacy-focused appeal and the NU7 network upgrade, while bears see further downside risk.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigettis Q3 revenue miss and lower-than-expected outlook are driving concern about its valuation and how soon quantum-computing development can translate into commercial sales. Some traders remain bullish on technical progress and government backing, while others focus on weak near-term revenue and speculate about a rebound or short squeeze.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

A Baird downgrade citing weaker visibility on future AI data-center spending and supply constraints is adding to pressure, while traders also debate allegations involving Jensen Huang and possible leadership or national-security fallout. Bulls argue AI demand remains strong and point to the rebound and CoreWeaves results, while skeptics see unresolved controversy and headline risk.

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Kura Oncology Inc

Kuras quarterly results and earnings call have put KOMZIFTIs commercial launch in focus, with traders citing rising prescriptions and new-patient starts as encouraging signs. Reactions are mixed: some are bullish on the launch and managements outlook, while others point to heavy put activity, a stock issuance filing and competition from J&J as risks.

Netlist, Inc. engages in the design, manufacture and sale of memory subsystems for the computing and communications markets. Its products include enterprise SSD, embedded flash, memory module, lightning DDR5 DIMM, SK hynix, AI server. The company was founded by Jayesh Bhakta, Chun Ki Hong and Christopher Lopes in June 2000 and is headquartered in Irvine, CA.

Netlist Inc

Netlists quarterly results showed sharply higher sales and improved profitability, prompting traders to focus on its Samsung and Micron licensing revenue and a shift toward a more recurring-revenue business. The community is especially bullish on CEO remarks suggesting SK Hynix could be the next licensing target, though no deal was confirmed and some traders questioned the muted share-price reaction and reported earnings-estimate miss.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

A report that nonprofit Usona may have filed an FDA application for psilocybin in major depression has stirred fears that Compass Pathways could lose its first-mover advantage, amid a sharp selloff. Traders dispute how much of a threat Usona poses given its different target indication and limited commercial infrastructure, while focusing on Compasss expected completion of the COMP360 application and its planned launch in 2027.

Bittensor (TAO) is a cryptocurrency launched in 2021and operates on the Bittensor platform. Bittensor has a current supply of 21,000,000 with 11,714,062.3012452 in circulation. The last known price of Bittensor is 218.6907284 USD and is down -1.27 over the last 24 hours. It is currently trading on 338 active market(s) with $106,454,109.48 traded over the last 24 hours. More information can be found at https://bittensor.com.

Bittensor

TAOs recent weakness and broader crypto risk-off sentiment have traders debating whether to wait for a deeper pullback or accumulate. Long-term bulls point to Bittensors decentralized-AI subnet growth and reported revenue, while skeptics say adoption and value capture remain unproven; the Anthropic IPO is also prompting speculation about how major AI listings could affect the sectors narrative.

Amprius Technologies, Inc. engages in the development, manufacture, and market of lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the following geographical segments: North America, EMEA, and Asia Pacific. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius quarterly results are driving attention: strong revenue growth and raised full-year guidance were offset by an earnings-per-share miss and weaker adjusted EBITDA, followed by a selloff. Traders are divided between viewing the growth and margin progress as encouraging and worrying that profitability remains uncertain.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$ABCL  
Stifel Nicolaus raised its price target on AbCellera Biologics  
from $9 to $14 and maintained a Buy rating. 
Analyst sentiment is broadly positive:  
ABCL has a “Moderate Buy” consensus rating  
and an average price target of $16.33. 
AbCellera beat quarterly estimates,  
reporting a $0.13-per-share loss versus the $0.17 consensus  
and revenue of $10.64 million versus $8.41 million expected,  
though it remains unprofitable.

Maikel van den Heuvel

Napoleon

TM Underhill

StockTwits Web

AbCellera Biologics Inc

  
Stifel Nicolaus raised its price target on AbCellera Biologics  
from $9 to $14 and maintained a Buy rating. 
Analyst sentiment is broadly positive:  
ABCL has a “Moderate Buy” consensus rating  
and an average price target of $16.33. 
AbCellera beat quarterly estimates,  
reporting a $0.13-per-share loss versus the $0.17 consensus  
and revenue of $10.64 million versus $8.41 million expected,  
though it remains unprofitable.